Search
Dimethylthiambutene
go.drugbank.com/drugs/DB01444ExperimentalIllicitIt is now under international control under Schedule I of the UN Single Convention On Narcotic Drugs 1961, presumably due to high abuse potential, although little more information is available. … Dimethylthiambutene (N,N-Dimethyl-1-methyl-3,3-di-2-thienylallylamine, Dimethibutin, Ohton) is an opioid analgesic drug.
Synonyms: N,N,1-trimethyl-3,3-di-2-thienylallylamine, N,N-dimethyl-4,4-di(2-thienyl)-3-buten-2-aminePelubiprofen
go.drugbank.com/drugs/DB12150InvestigationalPelubiprofen has been investigated for the treatment of Chronic Back Pain.
Categories: Antiinflammatory and Antirheumatic Products, Non-SteroidsElocalcitol
go.drugbank.com/drugs/DB06194ExperimentalElocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004).
Palifosfamide
go.drugbank.com/drugs/DB05668InvestigationalPalifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.
Anlotinib
go.drugbank.com/drugs/DB11885InvestigationalAnlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
Inecalcitol
go.drugbank.com/drugs/DB04796InvestigationalSynonyms: (7E)-19-Nor-9,10-seco-14beta-cholesta-5,7-dien-23-yne-1alpha,3beta,25-triolElsamitrucin
go.drugbank.com/drugs/DB05129InvestigationalThe cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873)
Lilotomab
go.drugbank.com/drugs/DB19076InvestigationalLilotomab is under investigation in clinical trial NCT01796171 (A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-hodgkin Lymphoma).
Ulotaront
go.drugbank.com/drugs/DB15665InvestigationalSEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. … Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5
Aranidipine
go.drugbank.com/drugs/DB09229Experimental[A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88] … Aranidipine is a novel dihydropyridine derivative that gives rise to two active metabolites (M-1α and M-1β) that exhibit hypotensive activity.